The Food and Drug Administration’s additional approval of the wrinkle-smoothing injection Botox as a treatment for migraine headaches should prove to be a “watershed” moment for Allergan Inc.’s revenue and earnings growth, according to a William Blair & Co. analyst. Ben Andrew said in a Monday morning research note that the new use could be worth $1 billion to Allergan’s top line within five years. “Based on our field work, we believe the market has not fully incorporated Allergan’s ability to drive revenue and earnings growth from this indication,”...

U.S. stocks traded lower Monday, as the Dow Jones Industrial Average fell 40 points to 10584, the Standard & Poor's 500 dropped 8 points to 1142 and the Nasdaq Composite Index slid 30 points to 2347. Among the companies whose shares are actively trading are Boston Scientific Corp. (BSX), Chordiant Software Inc. (CHRD) and Amylin Pharmaceuticals Inc. (AMLN). Boston Scientific ($6.50, -$1.28, -16.45%) shares fell on a report that the medical-device company had suspended sales of all implantable cardioverter defibrillators, or ICDs. According to an analyst note from Bernstein Research,...